Valuation: Brooks Laboratories Limited

Market Cap 1.88B 19.75M 17.69M 16.32M 14.77M 27.61M 28.06M 195M 77.67M 984M 74.11M 72.53M 3.12B P/E 2025
-28.6x
P/E 2026 4.45x
Enterprise Value 1.9B 19.94M 17.86M 16.48M 14.91M 27.88M 28.34M 197M 78.43M 994M 74.84M 73.25M 3.15B EV / Sales 2025
3.93x
EV / Sales 2026 1.3x
Free-Float
45.16%
Yield 2025 *
-
Yield 2026 -
09-16 Brooks Laboratories Limited Announces Resignation of Krutika Rane as Company Secretary and Compliance Officer (Key Managerial Personnel), Effective October 9, 2026 CI
08-13 Brooks Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
07-17 Brooks Laboratories Limited Announces Appointment of Rajesh Mahajan to President Trading and Senior Management Personnel, Effective July 17, 2026 CI
06-19 Steriscience Specialties Private Limited agreed to acquire an additional 16.33% stake in Brooks Steriscience Limited from Brooks Laboratories Limited for INR 1.1 billion. CI
05-29 Brooks Laboratories appoints Prashant Rathi as CEO RE
05-29 Brooks Laboratories names Prashant Rathi as CEO RE
05-29 Brooks Laboratories Limited Announces Appointment of Prashant Rathi as Chief Executive Officer, Effective June 1, 2026 CI
05-29 Brooks Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
02-07 Brooks Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
16/10/25 Brooks Laboratories Limited Announces That Mr. Rajesh Mahajan Resigned as President - Procurement, with Effect from 16 October 2025 CI
13/08/25 Brooks Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
29/05/25 Brooks Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2025 CI
13/02/25 Brooks Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
1 day+1.44%
1 week+11.93%
Current month+16.06%
1 month+16.06%
3 months+8.64%
6 months+15.68%
Current year-19.19%
1 week 55.5
Extreme 55.5
66
1 month 52.97
Extreme 52.97
75.6
Current year 36.3
Extreme 36.3
82.44
1 year 36.3
Extreme 36.3
116
3 years 36.3
Extreme 36.3
198.86
5 years 36.3
Extreme 36.3
198.86
10 years 13.85
Extreme 13.85
198.86
Manager TitleAgeSince
Chief Executive Officer 58 23/01/2002
Chief Executive Officer - 01/06/2026
President 58 23/08/2023
Director TitleAgeSince
Director/Board Member 53 23/11/2022
Director/Board Member 62 10/09/2010
Director/Board Member - 23/08/2023
Change 5-day change 1-year change 3-year change Capi.($)
+1.38%+11.93%-41.98%-39.42% 18.53M
+6.63%+5.13%+68.86%+145.20% 1,148B
+1.53%+2.84%+47.48%+89.01% 652B
+1.68%+1.96%+29.16%+109.31% 505B
+0.73%+2.45%+54.26%+68.96% 384B
+3.83%-0.62%+69.01%+42.32% 348B
+2.38%+2.65%+34.31%+57.95% 294B
+2.26%+0.55%+3.92%+28.92% 264B
+1.97%+3.01%+57.91%+76.14% 244B
+4.03%+5.36%+39.76%+116.14% 197B
Average +2.25%+2.04%+36.27%+69.45% 403.72B
Weighted average by Cap. +2.25%+2.89%+50.22%+95.97%

Financials

2025 2026
Net sales 826M 8.67M 7.77M 7.16M 6.48M 12.12M 12.32M 85.47M 34.1M 432M 32.54M 31.84M 1.37B 857M 9M 8.06M 7.44M 6.73M 12.59M 12.79M 88.76M 35.41M 449M 33.79M 33.07M 1.42B
Net income -99.67M -1.05M -937K -865K -783K -1.46M -1.49M -10.32M -4.12M -52.16M -3.93M -3.84M -165M 246M 2.58M 2.31M 2.13M 1.93M 3.61M 3.67M 25.45M 10.15M 129M 9.69M 9.48M 407M
Net Debt 75.39M 792K 709K 654K 592K 1.11M 1.12M 7.81M 3.11M 39.46M 2.97M 2.91M 125M 18.44M 194K 173K 160K 145K 271K 275K 1.91M 762K 9.65M 727K 711K 30.56M
Projected Income Statement - Annual - Brooks Laboratories Limited
Logo Brooks Laboratories Limited
Brooks Laboratories Limited is an India-based pharmaceutical manufacturing company. The Company specializes in supplying pharmaceutical products to government bodies, healthcare institutions, and large organizations. It operates through two segments, which include manufacturing and trading. The manufacturing segment comprises its own manufacturing operations and loan-licensing business relating to pharmaceutical products, ingredients, and intermediaries. The trading segment comprises principal-to-principal trading activities in pharmaceutical products, ingredients, and intermediaries. Its General Products offerings include Liquid Injection (Ampoules), Liquid Injection (Vials), Dry Powder Injections (Vials), Lyophilised Injections, Eye/Ear Drops, and Nasal Drops. The Company's Critical Care Division (CCD), operates through a robust distribution network, delivering injectables to hospitals and healthcare institutions across India.
Employees
347
Date Price Change Volume
30/10/26 ₹64.72 +1.38% 11,070
29/10/26 ₹63.84 +6.58% 135,117
28/10/26 ₹59.90 +0.30% 23,697
27/10/26 ₹59.72 +3.21% 24,757
26/10/26 ₹57.86 0.00% 53,859
  1. Stock Market
  2. Stocks
  3. BROOKS Stock